Olivia Martinez
Publications
- Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder. Am J Transplant. 2013; (4): 883-90
- Changes in natural killer cell subsets in pediatric liver transplant recipients. Pediatr Transplant. 2012; (2): 176-82
- Differential expression of microRNAs during allograft rejection. Am J Transplant. 2012; (5): 1113-23
- Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder. Pediatr Transplant. 2012; (3): 220-9
- Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas. PLoS One. 2012; (8): e42610
- Distinct roles for the NK cell-activating receptors in mediating interactions with dendritic cells and tumor cells. J Immunol. 2011; (1): 222-9
- MHC mismatch inhibits neurogenesis and neuron maturation in stem cell allografts. PLoS One. 2011; (3): e14787
- Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas. J Biol Chem. 2011; (43): 37368-78
- Acute rejection of small intestine allografts is associated with increased expression of toll-like receptors. Transplant Proc. 2010; (7): 2676-8
- Identification of the rat NKG2D ligands, RAE1L and RRLT, and their role in allograft rejection. Eur J Immunol. 2010; (6): 1748-57
- Induced tolerance to rat liver allografts involves the apoptosis of intragraft T cells and the generation of CD4(+)CD25(+)FoxP3(+) T regulatory cells. Liver Transpl. 2010; (2): 147-54
- MicroRNAs as immune regulators: implications for transplantation. Am J Transplant. 2010; (4): 713-9
- Toll-like receptor 4 contributes to small intestine allograft rejection. Transplantation. 2010; (12): 1272-7
- Activation of the JAK/STAT pathway in Epstein Barr virus+-associated posttransplant lymphoproliferative disease: role of interferon-gamma. Am J Transplant. 2009; (10): 2292-302
- Decreases in circulating CD4+CD25hiFOXP3+ cells and increases in intragraft FOXP3+ cells accompany allograft rejection in pediatric liver allograft recipients. Pediatr Transplant. 2009; (1): 70-80
- Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant. 2008; (6): 563-8
- Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant. 2008; (11): 2205-11
- Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation. 2008; (1): 145-9
- Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos. J Biol Chem. 2008; (52): 36573-85
- Epstein-Barr virus: evasive maneuvers in the development of PTLD. Am J Transplant. 2007; (2): 271-7
- Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol. 2007; (12): 8225-34
- Mutations to bid cleavage sites protect hepatocytes from apoptosis after ischemia/reperfusion injury. Transplantation. 2007; (6): 778-85
- Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation. 2007; (8): 1114-21
- CD72 down-modulates BCR-induced signal transduction and diminishes survival in primary mature B lymphocytes. J Immunol. 2006; (9): 5321-8
- EBV B lymphoma cell lines from patients with post-transplant lymphoproliferative disease are resistant to TRAIL-induced apoptosis. Am J Transplant. 2006; (5 Pt 1): 976-85
- EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J Immunol. 2006; (5): 3283-93
- NKp30 is a functional activation receptor on a subset of rat natural killer cells. Eur J Immunol. 2006; (8): 2170-80
- Reproduction and pregnancy in transplant recipients: current practices. Prog Transplant. 2006; (2): 127-32
- Basic concepts in transplant immunology. Liver Transpl. 2005; (4): 370-81
- IFN-gamma, produced by NK cells that infiltrate liver allografts early after transplantation, links the innate and adaptive immune responses. Am J Transplant. 2005; (9): 2094-103
- Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant. 2005; (7): 1592-9
- Identification, cloning, and characterization of a novel rat natural killer receptor, RNKP30: a molecule expressed in liver allografts. Transplantation. 2004; (1): 121-8
- Rapamycin Inhibits the Interleukin 10 Signal Transduction Pathway and the Growth of Epstein Barr Virus B-cell Lymphomas Cancer Research. 2003; (15): 4472
- Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res. 2003; (15): 4472-80
- CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses. J Immunol. 2002; (4): 1784-91
- Constitutive activation of Jak/STAT proteins in Epstein-Barr virus-infected B-cell lines from patients with posttransplant lymphoproliferative disorder. Transplantation. 2002; (3): 396-402
- Epstein-Barr virus infection is associated with endothelial Bcl-2 expression in transplant liver allografts. Transplantation. 2002; (3): 465-9
- Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation. 2002; (4): 501-10
- NK cells and transplantation. Transpl Immunol. 2002; (2-4): 111-4
- Apoptosis and allograft rejection in the absence of CD8+ T cells. Transplantation. 2001; (12): 1827-34
- Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver. 2001; (4): 272-9
- Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway. J Immunol. 2001; (9): 5404-11
- Radiolabeled annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation. Radiology. 2000; (3): 795-800
- Significance of detecting Epstein-Barr-specific sequences in the peripheral blood of asymptomatic pediatric liver transplant recipients. Liver Transpl. 2000; (1): 62-6
- Involvement of Fas-Fas ligand interactions in graft rejection. Int Rev Immunol. 1999; (5-6): 527-46
- Characterization of allograft rejection in an experimental model of small intestinal transplantation. J Gastrointest Surg. 1998 Jul-Aug; (4): 325-32
- Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl Surg. 1998; (3): 208-14
- Apoptosis as a mechanism of tissue injury in liver allograft rejection. Semin Liver Dis. 1998; (2): 153-67
- Application of in situ hybridization technique for quantitative assessment of ongoing symptomatic Epstein-Barr virus infection after living related liver transplantation. Clin Transplant. 1998; (2): 116-22
- CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation. 1998; (9): 1240-7
- CD8+ cells are not necessary for allograft rejection or the induction of apoptosis in an experimental model of small intestinal transplantation. J Immunol. 1998; (8): 3673-80
- Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. Transplantation. 1998; (9): 1248-55
- Human hepatocytes produce an isoform of FAS that inhibits apoptosis. Transplantation. 1998; (5): 713-21
- Cytokines are involved in the rejection of small intestine allografts. Transplant Proc. 1997; (3): 1802
- Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol. 1997; (9): 4045-51
- T cell receptor usage by cytotoxic T lymphocytes against autologous human melanoma. Anticancer Res. 1996 Nov-Dec; (6B): 3355-61
- Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol. 1996; (3 Pt 1): 311-20
- Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology. 1996; (1): 6-9
- Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. Transplantation. 1996; (6): 776-80
- Acute liver allograft rejection in the rat. An analysis of the immune response. Transplantation. 1995; (1): 97-102
- An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation. 1995; (4): 524-9
- Apoptosis as a mechanism of cell death in a rat model of liver allograft rejection. Transplant Proc. 1995; (1): 466-7
- Apoptosis as a mechanism of cell death in liver allograft rejection. Transplantation. 1995; (4): 621-5
- Characterization of cytokine expression in an animal model of acute liver allograft rejection. Transplant Proc. 1995; (1): 505-6
- Circulating intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in pediatric liver recipients. Transplant Proc. 1995; (1): 1148-9
- Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology. 1995; (1): 113-9
- Differential patterns of circulating intercellular adhesion molecule-1 (cICAM-1) and vascular cell adhesion molecule-1 (cVCAM-1) during liver allograft rejection. Transplantation. 1995; (4): 584-9
- Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. Transplant Proc. 1995; (1): 1146-7
- Elevated biliary interleukin 5 as an indicator of liver allograft rejection. Transpl Immunol. 1995; (4): 291-8
- Expression of cytokines and immune mediators during chronic liver allograft rejection. Transplantation. 1995; (12): 1533-8
- Expression of the cytotoxic T cell mediator granzyme B during liver allograft rejection. Transpl Immunol. 1995; (2): 162-6
- Interleukin-12: a possible cytotoxic T-lymphocyte differentiation factor in allograft recipients. Transplant Proc. 1995; (1): 459-60
- Long-term nonresponsiveness to a liver allograft may be cytokine mediated. Transplant Proc. 1995; (1): 241-2
- Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. Transplant Proc. 1995; (1): 1211-2
- Viral and immunologic aspects of Epstein-Barr virus infection in pediatric liver transplant recipients. Transplantation. 1995; (4): 519-24
- Evidence for a nonclassical pathway of graft rejection involving interleukin 5 and eosinophils. Transplantation. 1993; (4): 909-18
- IL-2 and IL-5 gene expression in response to alloantigen in liver allograft recipients and in vitro. Transplantation. 1993; (5): 1159-66
- Intragraft eosinophilia and interleukin-5 mRNA accompany liver allograft rejection. Transplant Proc. 1993; (1 Pt 1): 126-7
- New immunologic insights into mechanisms of allograft rejection. Gastroenterol Clin North Am. 1993; (2): 381-400
- T-cell receptor-V alpha gene use in sequential liver allograft biopsies. Transplant Proc. 1993; (1 Pt 1): 84-5
- Intragraft cytokine profile during human liver allograft rejection. Transplantation. 1992; (2): 449-56
- Allogeneic hepatocytes stimulate the production of immunoregulatory molecules in mixed lymphocyte hepatocyte cultures. Transplant Proc. 1991; (1 Pt 1): 805-6
- MHC expression on human hepatocytes before and after isolation. Transplant Proc. 1991; (1 Pt 2): 1428-9
- Altered monocyte function in uremia. Clin Immunol Immunopathol. 1990; (1): 66-80
- IL-4 inhibits IL-2 receptor expression and IL-2-dependent proliferation of human T cells. J Immunol. 1990; (6): 2211-5
- Reduction in HLA-DR, HLA-DQ and HLA-DP expression by Leu-M3+ cells from the peripheral blood of patients with thermal injury. Clin Exp Immunol. 1989; (3): 371-5
Help
Trial Administration